Phase 2 Interstitial Lung Disease Trial, Recruiting (NCT06189820)

Phase 2 Interstitial Lung Disease Trial, Recruiting NCT06189820 Sponsor: Erasme University Hospital Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06189820 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults who have been diagnosed with a fibrotic lung disease, either idiopathic pulmonary fibrosis (IPF) or another type of fibrotic interstitial lung disease (a condition where the lungs develop scar tissue), as defined by international medical guidelines from 2022.

Who may not be able to join:

People who are pregnant or currently breastfeeding.
People who have another serious medical condition that, in the treating doctor's opinion, could interfere with completing the study.
People who have an active lung cancer or any other active cancer (this applies specifically to the blood sample part of the study — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: + 32 (2) 555 5758

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06189820

Sponsor: Erasme University Hospital

Phase: Phase 2

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: + 32 (2) 555 5758

More information: https://clinicaltrials.gov/study/NCT06189820

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults who have been diagnosed with a fibrotic lung disease, either idiopathic pulmonary fibrosis (IPF) or another type of fibrotic interstitial lung disease (a condition where the lungs develop scar tissue), as defined by international medical guidelines from 2022.

Who may not be able to join:

People who are pregnant or currently breastfeeding.
People who have another serious medical condition that, in the treating doctor's opinion, could interfere with completing the study.
People who have an active lung cancer or any other active cancer (this applies specifically to the blood sample part of the study — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Erasme University Hospital

Registry

ClinicalTrials.gov

Start date

9 March 2023

Est. completion

9 March 2027

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

FAPI uptake on PET/CT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov